NCI-H1623Homo sapiens (Human)Cancer cell line

Also known as: NCIH1623, H-1623, H1623

🤖 AI SummaryBased on 10 publications

Quick Overview

Human lung cancer cell line with known RB1 mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H1623 cell line is a human lung cancer cell line derived from a patient with non-small cell lung cancer. It is characterized by mutations in the RB1 gene, which is a key tumor suppressor involved in cell cycle regulation. These mutations contribute to the uncontrolled proliferation of cancer cells. The cell line is widely used in research to study the molecular mechanisms of lung cancer and to evaluate the efficacy of potential therapeutic agents. Its genetic profile makes it a valuable model for understanding the role of RB1 in cancer progression and for developing targeted therapies.

Research Applications

Molecular mechanisms of lung cancerRB1 gene mutation studiesDrug sensitivity testing

Key Characteristics

RB1 gene mutationsHuman lung cancer model
Generated on 6/17/2025

Basic Information

Database IDCVCL_1481
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age58
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000744_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg273Leu (c.818G>T)HomozygousSomatic mutation acquired during proliferationPubMed=31541927, PubMed=23613873, PubMed=15735012

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
9
D13S317
12
D16S539
9,12
D18S51
14
D19S433
13
D21S11
30.2,31.2
D2S1338
19,24
D3S1358
18
D5S818
12
D7S820
8
D8S1179
13,14
FGA
20,23
Penta D
14
Penta E
7
TH01
7
TPOX
11
vWA
15,19,20
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

J. Natl. Cancer Inst. 102:1310-1321(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources